Recro Pharma (REPH) Tops Q1 EPS by 96c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Pharma Reports First Quarter 2019 Financial Results
May 10, 2019 7:02 AM EDTCompany to Host Conference Call Today at 8:00 AM ET
MALVERN, Philadelphia, May 10, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ: REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three months ended March 31, 2019.
Our CDMO business is off to a strong start this year, generating $25.1 million in first quarter revenues, a 28% increase from the prior year first quarter, said Gerri Henwood, President and Chief Executive Officer of Recro... More
